Ultragenyx Pharmaceutical Inc. (RARE)
| Market Cap | 2.52B -13.2% |
| Revenue (ttm) | 717.00M +17.5% |
| Net Income | -586.00M |
| EPS | -5.83 |
| Shares Out | 98.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,612,866 |
| Open | 26.54 |
| Previous Close | 26.26 |
| Day's Range | 25.37 - 26.73 |
| 52-Week Range | 18.29 - 39.89 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 55.05 (+114.96%) |
| Earnings Date | Aug 4, 2026 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2025, Ultragenyx Pharmaceutical's revenue was $673.00 million, an increase of 20.18% compared to the previous year's $560.00 million. Losses were -$575.00 million, 1.05% more than in 2024.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $55.05, which is an increase of 114.96% from the latest price.
News
Ultragenyx price target raised to $50 from $46 at Wells Fargo
Wells Fargo raised the firm’s price target on Ultragenyx (RARE) to $50 from $46 and keeps an Overweight rating on the shares. Ahead of the GTX-102 Phase 3 Angelman Syndrome…
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...
Ultragenyx price target raised to $80 from $75 at JPMorgan
JPMorgan raised the firm’s price target on Ultragenyx (RARE) to $80 from $75 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotech space.
Ultragenyx price target raised to $74 from $67 at Morgan Stanley
Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Ultragenyx (RARE) to $74 from $67 and keeps an Overweight rating on the shares. Genglycos’ accelerated approval marks Ultragenyx’s...
Ultragenyx price target raised to $48 from $46 at BofA
BofA raised the firm’s price target on Ultragenyx (RARE) to $48 from $46 and keeps a Buy rating on the shares. Ultragenyx’s Genglycos received accelerated FDA approval for GSD1a, with…
Ultragenyx Pharmaceutical (RARE) Stock Jumps 9% on Accelerated FDA Approval
Ultragenyx Pharmaceutical stock rallied 8.99% on Thursday after the FDA granted Ultragenyx Pharmaceutical’s GENGLYCOS accelerated approval.
Ultragenyx price target raised to $103 from $96 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Ultragenyx (RARE) to $103 from $96 and keeps an Overweight rating on the shares. Ultragenyx’s FDA approval of GENGLYCOS provides an important…
Ultragenyx price target raised to $83 from $81 at Canaccord
Canaccord raised the firm’s price target on Ultragenyx (RARE) to $83 from $81 and keeps a Buy rating on the shares. The firm said as expected, Ultragenyx’s gene therapy for…
Ultragenyx price target raised to $46 from $45 at Wells Fargo
Wells Fargo raised the firm’s price target on Ultragenyx (RARE) to $46 from $45 and keeps an Overweight rating on the shares. Though not central to the main debate regarding…
Ultragenyx price target raised to $58 from $45 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Ultragenyx (RARE) to $58 from $45 and keeps a Buy rating on the shares. The firm cites approval of Genglycos…
Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod
The U.S. Food and Drug Administration approved Ultragenyx Pharmaceutical's gene therapy to treat a rare metabolic disorder, the company said on Wednesday.
Ultragenyx announces FDA accelerated approval of Genglycos
Ultragenyx (RARE) Pharmaceutical announced that the FDA granted accelerated approval for Genglycos, also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage di...
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to reduce the burden of care associated with GSDIa Ultr...
Ultragenyx Pharmaceutical Transcript: Status update
GENGLYCOS received FDA approval as the first gene therapy for GSDIa, with rapid commercial launch planned and strong anticipated demand due to urgent unmet need. The company will collect confirmatory data, expand treatment centers, and pursue global commercialization, with net pricing expected near $2 million.
Ultragenyx Pharmaceutical Press release: Status update
Ultragenyx Pharmaceutical issued a press release on August 19, 2026, disclosing material business information to investors.
Ultragenyx price target raised to $81 from $79 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $81 from $79 and keeps a Buy rating on the shares. The firm said 2Q26 earnings report…
Ultragenyx price target lowered to $45 from $47 at Wells Fargo
Wells Fargo lowered the firm’s price target on Ultragenyx (RARE) to $45 from $47 and keeps an Overweight rating on the shares. The firm is constructive ahead of GTX-102 Phase…
Ultragenyx Pharmaceutical Earnings Call Transcript: Q2 2026
Record Q2 revenue of $214M driven by strong global demand and commercial execution. Two gene therapies, DTX-401 and UX-111, are under FDA review with launches anticipated soon, while phase III data for GTX-102 in Angelman syndrome is expected in the fall. Cash position remains strong at $436M.
Ultragenyx Pharmaceutical Earnings release: Q2 2026
Ultragenyx Pharmaceutical released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Ultragenyx Pharmaceutical Quarterly report: Q2 2026
Ultragenyx Pharmaceutical has published its Q2 2026 quarterly earnings report on August 4, 2026.
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
Second quarter total revenue of $214 million, Crysvita® revenue of $156 million and Dojolvi® revenue of $27 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 m...
Ultragenyx price target lowered to $35 from $43 at Guggenheim
Guggenheim lowered the firm’s price target on Ultragenyx (RARE) to $35 from $43 and keeps a Buy rating on the shares. Should the ASPIRE readout in Q3 be overwhelmingly positive,…
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
NOVATO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) agains...
Ultragenyx price target raised to $30 from $26 at Wedbush
Wedbush raised the firm’s price target on Ultragenyx (RARE) to $30 from $26 and keeps a Neutral rating on the shares. The firm updated its model ahead of the Q2…